T he metabolic syndrome (MetS) describes a clustering of cardiovascular risk factors in individuals that may greatly increase their risk of vascular and metabolic disease. [1] [2] [3] Although different diagnostic criteria have been proposed by the National Cholesterol Education Program's Adult Treatment Panel III (ATP-III), 4, 5 the World Health Organization (WHO), 6 the International Diabetes Federation (IDF), 7 and the European Group for the Study of Insulin Resistance (EGIR), 8 all of these definitions include measures of glucose intolerance, hypertension, obesity, hypertriglyceridemia, and decreased high-density lipoprotein (HDL) cholesterol as part of the syndrome. The value of MetS is primarily its promise to identify asymptomatic individuals thought to be at increased risk of cardiovascular disease (CVD) 9 for whom increased clinical surveillance and earlier institution of risk-modifying therapies might be appropriate. Its utility, however, is being increasingly questioned. 10, 11 
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Glucose intolerance is a component of all current MetS definitions, but it remains a matter for debate whether people with established type 2 diabetes mellitus (T2DM) should be included within this criterion. T2DM is a well-established CVD risk factor thought by some authors to be a coronary heart disease risk equivalent. [11] [12] [13] Because the diagnosis of T2DM should prompt detailed clinical evaluation and treatment of all CVD risk factors, including those that are MetS components, the degree to which identifying MetS in T2DM patients might be helpful in clinical practice remains uncertain. However, if the presence of MetS in T2DM patients does identify those at greatly increased risk of diabetic complications, even more stringent treatment goals for blood pressure and lipids may be indicated for these patients. We have used United Kingdom Prospective Diabetes Study (UKPDS) data to assess the impact of MetS on future risk of developing both macrovascular and microvascular clinical outcomes in patients with newly diagnosed T2DM.
Methods

Study Participants
The UKPDS was a clinical trial designed to evaluate the effects of more intensive blood glucose and/or tighter blood pressure control on the incidence of complications in patients with T2DM. 14, 15 It received ethics committee approval in all 23 participating clinical centers and conformed to the guidelines of the Declarations of Helsinki. Briefly, 5102 of 7616 patients referred with newly diagnosed T2DM entered the study between 1977 and 1991 and provided informed consent. They were 25 to 65 years of age and had fasting plasma glucose (FPG) levels Ͼ6.0 mmol/L on 2 occasions after T2DM was diagnosed. On self-reported ethnicity, 81% were white Caucasian, 10% Indian Asian, and 9% Afro-Caribbean. After a 3-to 4-month dietary run-in, therapies for glycemic control were allocated randomly according to the UKPDS protocol. A subset of hypertensive participants (nϭ1148) were subsequently also allocated randomly to therapies for blood pressure control. 16 All patients were followed up quarterly in UKPDS clinics for up to 20 years (median 10.3 years).
Retrospective analyses were performed on 4542 individuals who had the requisite data for MetS components available after their dietary run-in. UKPDS biochemical and clinical measurement methods have been described previously. 14, 17 
MetS Definitions
Four definitions of MetS were used in the present analysis: ATP-III, WHO, IDF, and EGIR. ATP-III 4 requires the presence of any 3 of 5 criteria: (1) FPG Ͼ6.0 mmol/L; (2) waist circumference Ͼ102 cm (men) or Ͼ88 cm (women); (3) triglycerides Ն1.7 mmol/L; (4) HDL cholesterol Ͻ1.0 mmol/L (men) or Ͻ1.3 mmol/L (women); and (5) blood pressure Ն130/85 mm Hg or current use of antihypertensive therapy (ie, known hypertension). WHO 6 requires either known diabetes mellitus, FPG Ͼ6.0 mmol/L, or insulin resistance in the highest quartile for the population, in addition to at least 2 of the following: (1) waist-hip-ratio Ͼ0.9 (men) or Ͼ0.85 (women) or body mass index Ͼ30 kg/m 2 ; (2) triglycerides Ն1.7 mmol/L; (3) HDL cholesterol Ͻ0.9 mmol/L (men) or Ͻ1.0 mmol/L (women), (4) blood pressure Ն160/90 mm Hg or known hypertension; or (5) urinary albumin Ͼ50 mg/L, albumin-to-creatinine ratio Ն20 mg/g, or urinary albumin excretion rate Ն20 g/min. IDF 7 requires central obesity (defined by waist circumference Ͼ94 cm in white Caucasian or Afro-Caribbean men, Ͼ90 cm in Indian Asian men, or Ͼ80 cm in women), in addition to at least 2 of the following: (1) known diabetes mellitus or FPG Ͼ5.6 mmol/L; (2) triglycerides Ն1.7mmol/L; (3) HDL cholesterol Ͻ0.9 mmol/L (men) or Ͻ1.0 mmol/L (women); or (4) blood pressure Ն135/85 mm Hg or known hypertension. EGIR 8 requires patients to have insulin resistance (defined by lowest quartile for homeostasis model assessment of insulin sensitivity 18 in the general population), in addition to at least 2 of the following: (1) known diabetes mellitus or FPG Ͼ6.0 mmol/L; (2) waist circumference Ͼ94 cm (men) or Ͼ80 cm (women); (3) triglycerides Ͼ2.0 mmol/L; (4) HDL cholesterol Ͻ1.0 mmol/L; or (5) blood pressure Ն140/90 mm Hg or known hypertension. We derived the lowest homeostasis model assessment of insulin sensitivity quartile (77.8%) from the population of nondiabetic individuals recruited to determine UKPDS reference ranges. 17 
End Points
Four composite outcomes were examined: (1) CVD, defined as the first to occur of sudden death, fatal or nonfatal myocardial infarction (MI), or fatal or nonfatal stroke; (2) MI, defined as the first to occur of sudden death or fatal or nonfatal MI; (3) stroke, defined as the first 
Statistical Analysis
Statistical analyses were performed with SAS versions 8.2 and 9.1.3 (SAS Institute Inc, Cary, NC). Data are reported as mean (SD), geometric mean (1-SD interval), median (interquartile range), or percentages. The homeostasis model assessment calculator (available at http://www.dtu.ox.ac.uk/homa) was used to estimate ␤-cell function and insulin sensitivity. 18 The UKPDS risk engine 19, 20 was used to estimate 10-year CVD risks. Comparisons between groups used 2-sample t tests or the Wilcoxon signed rank test for nonnormally distributed data. Categorical comparisons used the 2 test or Fisher's exact test. The Cochran-Armitage test for trend, the -test for agreement, and the Breslow-Day test for homogeneity of odds ratios were used as appropriate. Kaplan-Meier survival analysis of time to event with the log-rank test was used for comparison of groups with and without MetS. Proportional hazards models were used to derive hazard ratios as estimates of relative risk, which are quoted with 95% confidence intervals. Absolute risks are quoted as events per 1000 person-years. To allow for multiple testing, only probability values Ͻ0.01 were considered significant. Discrimination with respect to CVD for the 4 different definitions of MetS was compared by calculating CVD specificity, sensitivity, positive predictive value, and likelihood ratios.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written. (Figure) . Of those without ATP-III MetS, 47% had 10-year estimated CVD risks Ն20%, whereas 37% of those with ATP-III MetS had 10-year estimated CVD risks Ͻ20%.
Results
Discussion
We have shown in the present study that individuals with newly diagnosed T2DM exhibit a high prevalence of MetS, whether defined by ATP-III, WHO, IDF, or, to a lesser degree, EGIR criteria. MetS, diagnosed by any of these definitions, identifies diabetic patients at higher risk of future macrovascular but not microvascular complications. MetS, however, is a poor discriminator of CVD outcomes in individual patients and as such is of limited clinical value for CVD risk stratification in T2DM.
Previous studies have demonstrated a high prevalence of MetS consistently in diabetic populations. 2, [21] [22] [23] The present report extends these observations by evaluating 4 definitions of MetS simultaneously in the UKPDS cohort. In this population with newly diagnosed T2DM, we confirm the high prevalence of MetS, although this varies markedly according to the criteria used (ATP-III 60.8%, IDF 54.1%, WHO 38.4%, and EGIR 23.4%). The much smaller proportion detected by the EGIR criteria suggests that this definition may differ substantially from the other 3. The prospective impact of MetS on incident vascular disease in patients with T2DM has been unclear to date because of conflicting results in previous studies addressing this question. In a study of 946 diabetic patients followed up for a mean of 4.5 years, Bonora et al 22 reported that WHO-defined MetS at baseline was associated independently with incident CVD. In another study of 750 patients (164 with diabetes) followed up over 2.3 years, ATP-III-defined MetS remained a significant determinant of future vascular events in both the diabetic and normoglycemic cohorts. 24 In contrast, the Casale Monferrato Study reported that WHO-defined MetS was not associated with 11-year all-cause or CVD mortality in a population-based cohort of 1565 patients with T2DM. 21 Furthermore, in an 8-year study of 1424 Japanese patients with T2DM in which both WHO and ATP-III definitions were evaluated, only WHO-defined MetS in female patients was related to incident CVD, which led the authors to suggest that the clinical utility of these definitions is limited in Asian diabetic patients. 23 The present analysis provides an opportunity to address these conflicting observations by evaluating multiple definitions simultaneously in a large, well-characterized cohort with Ͼ50 000 person-years of follow-up. By ATP-III, WHO, IDF, and EGIR criteria, MetS at baseline emerged as a consistent independent risk factor for CVD, MI, and stroke but not for microvascular complications. Thus, these data suggest that MetS, whether defined by ATP-III, WHO, IDF, or EGIR criteria, can help identify diabetic patients at risk of future macrovascular but not microvascular disease.
In clinical diabetes care, the practical value of a concept such as MetS rests on its ability to characterize risk for individual patients. Currently, such risk estimation in patients with T2DM can be accomplished with the UKPDS risk engine, a diabetes-specific model that estimates CVD risk on the basis of continuous measures of conventional risk factors. 19 In the present analyses, there was considerable overlap in estimated 10-year CVD risks between patients with and without MetS. Indeed, 47% of those without ATP-III MetS had estimated 10-year CVD risks Ն20%, a threshold at which risk-modifying intervention is often recommended, and identification of MetS carried a low positive predictive value for CVD outcomes.
Several factors are likely to contribute to the poor discriminative capacity of MetS in this context. Because risk factors such as blood pressure, lipid levels, and blood glucose levels show continuous relationships with vascular disease, it is not surprising that dichotomized thresholds such as those used for MetS criteria should fail to capture fully the risk associated with these parameters. 11 Furthermore, although the various definitions of MetS give weight to each of their components equally, it is clear that some risk factors carry greater CVD prognostic capacity than others. This issue is particularly relevant in patients with diabetes mellitus, because glucose intolerance exhibits a disproportionate impact on CVD risk compared with some other MetS components. Indeed, the presence of impaired FPG (FPG Ͼ6.1 mmol/L) alone has emerged as a stronger predictor of CVD and all-cause 128 (17) 141 (20) 134 (20) 138 (19) 79 (9) 86 (10) 82 (10) 85 (10) 24.7 (3.5) 30.1 (5.4) 26.6 (4.6) 31.5 (6.0) Ͻ0.0001
89 (9) 106 (10) 95 (11) 105 (13) 82 (12) 99 (12) 90 (13) 102 (14) 0 associated with MetS was entirely driven by diabetes mellitus and that this excess risk could be eliminated on controlling for diabetes. Thus, the present findings are consistent with earlier reports and serve to emphasize the limited additional information regarding CVD risk stratification conveyed by MetS in the setting of T2DM. Because the majority of patients in these analyses were randomized to different policies of glucose control in the UKPDS, and a subset of individuals were also randomized subsequently to different blood pressure control policies, an interaction between the presence of MetS and allocated therapies cannot be ruled out. However, the distribution of patients with and without MetS was found to be similar in both trial allocations (data not shown), which suggests that any interaction would not alter the conclusions reported here. 
